William Hartsell
Overview
Explore the profile of William Hartsell including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
776
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Roehrig A, Indelicato D, Paulino A, Ermoian R, Hartsell W, Perentesis J, et al.
J Neurooncol
. 2023 Jul;
164(1):269.
PMID: 37498475
No abstract available.
2.
Roehrig A, Indelicato D, Paulino A, Ermoian R, Hartsell W, Perentesis J, et al.
J Neurooncol
. 2023 Mar;
162(2):353-362.
PMID: 36951945
Purpose: Atypical teratoid/rhabdoid tumors (ATRT) of the central nervous system (CNS) are rare tumors with a poor prognosis and variable use of either focal or craniospinal (CSI) radiotherapy (RT). Outcomes...
3.
Hasan S, Lazarev S, Garg M, Gozland R, Chang J, Hartsell W, et al.
Prostate
. 2023 Mar;
83(9):850-856.
PMID: 36946610
Background: Data for proton therapy in high-risk prostate cancer (HRPC) are limited. Using the Proton Collaborative Group prospective registry, we evaluated outcomes for HRPC patients treated with proton therapy. Methods:...
4.
Jongen A, Charlier F, Baker K, Chang J, Hartsell W, Laramore G, et al.
Adv Radiat Oncol
. 2022 Jan;
7(1):100767.
PMID: 35071826
Purpose: For most disease sites, level 1 evidence is lacking for proton beam therapy (PBT). By identifying target populations that would benefit most from PBT, prospective registries could overcome many...
5.
Parzen J, Chuong M, Chang J, Rosen L, Urbanic J, Hartsell W, et al.
Adv Radiat Oncol
. 2021 Oct;
6(5):100751.
PMID: 34646969
Purpose: Concurrent chemoradiation plays an integral role in the treatment of esophageal cancer. Proton beam radiation therapy has the potential to spare adjacent critical organs, improving toxicity profiles and potentially...
6.
Hubbard A, Mantz C, Mohideen N, Hartsell W, Thaker N, Orio P, et al.
JCO Oncol Pract
. 2021 Sep;
17(12):777-781.
PMID: 34524836
In its current form, the Radiation Oncology Model (RO Model) prioritizes payment cuts over true value-based payment transformation. With significant modifications to the payment methodology, the reporting requirements, and recognition...
7.
Tseng Y, Pankuch M, Mohindra P, McGee L, Rossi C, Flampouri S, et al.
Am J Clin Oncol
. 2021 Apr;
44(6):269-274.
PMID: 33852456
Purpose: As patients with mediastinal lymphoma are typically young with curable disease, advanced radiation techniques such as proton therapy are often considered to minimize subacute and late toxicity. However, it...
8.
Han J, Chang J, Rosen L, Hartsell W, Tsai H, Chen J, et al.
Clin Transl Radiat Oncol
. 2020 Nov;
25:94-101.
PMID: 33204857
Introduction: To date, no studies examining the effect of treatment interruptions (TI) with proton beam therapy (PBT) have been published. The goal of our study was to determine the predictors...
9.
Parzen J, Hartsell W, Chang J, Apisarnthanarax S, Molitoris J, Durci M, et al.
Radiat Oncol
. 2020 Nov;
15(1):255.
PMID: 33148296
Background: Recent advances in radiotherapy techniques have allowed ablative doses to be safely delivered to inoperable liver tumors. In this setting, proton beam radiotherapy (PBT) provides the means to escalate...
10.
Mishra M, Khairnar R, Bentzen S, Larson G, Tsai H, Sinesi C, et al.
Clin Transl Radiat Oncol
. 2020 Apr;
22:50-54.
PMID: 32258443
Background: Although pencil beam scanning (PBS) is the most conformal method for proton beam therapy (PBT) delivery, it is unknown if outcomes differ compared to treatment with passive scatter/uniform scanning...